Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.

Yu Feng Yunxia TaoHaizhu ChenYu ZhouLe TangChenwei LiuXing-Sheng Hu Yuan-Kai Shi

Published in: Thoracic cancer (2023)

ICI rechallenge is a useful therapeutic strategy for NSCLC patients, especially suitable for those who achieve long-term tumor remission for more than 2-years under 1L-ICIs.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
prognostic factors
rheumatoid arthritis
advanced non small cell lung cancer
brain metastases